Evidence map›Paper›PMID 31337344›Full record

Observational studyBMC infectious diseases2019

Self-reported diabetes and herpes zoster are associated with a weak humoral response to the seasonal influenza A H1N1 vaccine antigen among the elderly.

Manas K Akmatov, Peggy Riese, Stephanie Trittel, Marcus May, Jana Prokein, Thomas Illig, Christoph Schindler, Carlos A Guzmán, Frank Pessler

Registry-linked trialOpen access · goldAbstract readObservational Study
In one paragraph

Observational study in BMC infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02362919 (Determinants of Vaccine Response to Influenza Vaccination Among Individuals Over 65 Years of Age - a Population-based Study), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02362919 completednot on this map

Determinants of Vaccine Response to Influenza Vaccination Among Individuals Over 65 Years of Age - a Population-based Study

TypeobservationalSponsorHelmholtz Centre for Infection ResearchRan2015 to 2016Enrolled200ConditionsInfluenza
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Trial
  2. Article
  3. Observational
  4. Article
  5. Article
  6. Review
  7. Temporal Profile and Treatment ofInternational medical case reports journal · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Manas K AkmatovHelmholtz Centre for Infection Research, Braunschweig, Germany. makmatov@zi.de.ORCID http://orcid.org/0000-0003-2310-3179
Peggy RieseDepartment of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Braunschweig, Germany.
Stephanie TrittelDepartment of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Braunschweig, Germany.
Marcus MayClinical Research Center Hannover, Hannover Medical School, Hannover, Germany.
Jana ProkeinHannover Unified Biobank, Hanover Medical School, Hannover, Germany.
Thomas IlligHannover Unified Biobank, Hanover Medical School, Hannover, Germany.
Christoph SchindlerClinical Research Center Hannover, Hannover Medical School, Hannover, Germany.
Carlos A GuzmánCentre for Individualised Infection Medicine, Hannover, Germany.
Frank PesslerHelmholtz Centre for Infection Research, Braunschweig, Germany.
Helmholtz Centre for Infection Research · DEMedizinische Hochschule Hannover · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe immune response to seasonal influenza vaccines decreases with advancing age. Therefore, an adjuvanted inactivated trivalent influenza vaccine (Fluad®) exists for elderly individuals. Fluad® is more immunogenic and efficacious than conventional influenza vaccines. However, the immune response varies and may still result in high frequencies of poor responders. Therefore, we aimed to a) examine the prevalence of a weak response to Fluad® and b) identify potential risk factors.

methodsA prospective population-based study among individuals 65-80 years old was conducted in 2015/2016 in Hannover, Germany (n = 200). Hemagglutination-inhibition titers 21 days after vaccination with Fluad® served as indicator of vaccine responsiveness.

resultsThe percentage of vaccinees with an inadequate vaccine response varied depending on the influenza strain: it was lowest for H3N2 (13.5%; 95% CI, 9.4-18.9%), intermediate for B strain (37.0%; 30.6-43.9%), and highest for H1N1 (49.0%; 42.2-55.9%). The risk of a weak response to the influenza A H1N1 strain was independently associated with self-reported diabetes (AOR, 4.64; 95% CI, 1.16-18.54), a history of herpes zoster (2.27; 1.01-5.10) and, to a much lesser extent, increasing age (change per year, 1.08; 0.99-1.16). In addition, herpes zoster was the only risk factor for a weak response to the H3N2 antigen (AOR, 3.12; 1.18-8.23). We found no significant association between sex, Body Mass Index, cancer, hypertension, heart attack and CMV seropositivity and a weak response to these two influenza A antigens. Despite its occurence in over one third of vaccinees, none of the variables examined proved to be risk factors for a weak response to the B antigen.

conclusionsA considerable proportion of elderly individuals displayed a weak vaccine response to this adjuvanted seasonal influenza vaccine and further efforts are thus needed to improve immune responses to influenza vaccination among the elderly. Diabetes and herpes zoster were identified as potentially modifiable risk factors for a poor vaccine response against influenza A antigens, but the results also reveal the need for broader investigations to identify risk factors for inadequate responses to influenza B antigens.

trial registrationNo. NCT02362919 (ClinicalTrials.gov, date of registration: 09.02.2015).

Indexed as

Immunity, HumoralAdjuvants, ImmunologicAgedAged, 80 and overAntigens, ViralDiabetes MellitusFemaleGermanyHerpes ZosterHumansInfluenza A Virus, H1N1 SubtypeInfluenza A Virus, H3N2 SubtypeInfluenza, HumanInfluenza VaccinesMaleProspective StudiesAdjuvants, ImmunologicAntigens, Viralfluad vaccineInfluenza VaccinesDiabetesElderlyFluad®Herpes zosterInfluenza vaccination

Identifiers

PMID31337344
PMCPMC6651912
OpenAlexW2963847697

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.